Molecular Biology of Anal Cancer in HIV-Positive Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The molecular mechanisms involved in squamous cell carcinoma of the anus (SCCA) are poorly elucidated. HIV-positive and renal transplant patients are at high risk for developing SCCA, indicating that immune suppression plays a facilitating role. The investigators previously demonstrated that chromosomal instability (CIN) was more prevalent in SCCA of HIV-negative than HIV-positive patients. Hence, the investigators postulate that microsatellite instability (MSI), another molecular pathway, might be a feature of SCCA progression in the HIV-positive population.
Study Aims:
- to determine the prevalence of MSI in paraffin-embedded tumor specimen of 15 patients from the Swiss HIV cohort who underwent surgical excision for SCCA; and
- eventually, to test our hypothesis by assessing the MSI status of SCCA in 15 recently operated HIV-negative patients.
Study Design:
The study is designed in two steps:
- Firstly, the investigators will retrieve tumor specimen from 15 HIV-positive patients, with a biopsy-confirmed diagnosis of SCCA, in three institutions. DNA from tumor and normal tissues will be extracted, and then amplified by PCR. Presence of MSI in tumors will be determined by assessing the microsatellite markers BAT25, BAT26, and CAT25.
- Secondly, the results of molecular analysis will be compared with a population of HIV-negative patients, with the same tumors, using the same detection technique for MSI.
Condition |
---|
Carcinoma HIV Infections |
Study Type: | Observational |
Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
Official Title: | Microsatellite Instability in Anal Squamous Cell Carcinomas of HIV-Positive Versus HIV-Negative Patients |
Biosie of anal cancer
Estimated Enrollment: | 30 |
Study Start Date: | July 2009 |
Study Completion Date: | June 2010 |
Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
HIV positive and negative patients with biopsy proven squamous cell carcinoma of the anal canal
Inclusion Criteria:
- Biopsy proven Squamous cell carcinoma of the anus
- Informed consent
Exclusion Criteria:
- None
Switzerland | |
University Hospital Geneva | |
Genève, Switzerland, 1211 |
Study Chair: | Bernard Hirschel | Swidd HIV cohort |
No publications provided
Responsible Party: | Pascal Gervaz, Department of Surgery, University Hospital Geneva |
ClinicalTrials.gov Identifier: | NCT00952874 History of Changes |
Other Study ID Numbers: | SCCA/HIV |
Study First Received: | August 3, 2009 |
Last Updated: | June 24, 2010 |
Health Authority: | Switzerland: Federal Office of Public Health |
Keywords provided by University Hospital, Geneva:
anal cancer Molecular biology HIV status HPV infection |
Microsatellite instability Biopsy proven Squamous Cell carcinoma of the Anus Squamous Cell carcinoma of the Anus |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Anus Neoplasms Carcinoma Carcinoma, Squamous Cell HIV Seropositivity Microsatellite Instability Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Slow Virus Diseases Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Anus Diseases Rectal Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
ClinicalTrials.gov processed this record on February 26, 2013